Overview

3-AP in Treating Patients With Advanced Prostate Cancer

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 3-AP in treating patients who have advanced prostate cancer that has been previously treated with hormone therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Vion Pharmaceuticals